ICU Medical, Incorporated (ICUI) 2010年年度报告「NASDAQ」.pdf

1、2010Annual Report to Shareholdersand Form 10-K951 Calle Amanecer San Clemente,CA 92673 (949)366-2183 (800)824-7890 Fax(949)366-8368 March 21,2011 Dear Stockholder:2010 was a successful year for ICU Medical due to many improving aspects of our business.We reported record sales of$284.6 million,record

2、 net income of$30.9 million,or a$2.23 per diluted share,and continued to make strategic investments in many facets of our business in order to build upon our proven track record of industry-leading products,manufacturing capabilities and customer satisfaction.Our strong top line growth was driven by

3、 double digit improvements in all products lines.Domestic distributors and direct sales were up 54%,while international revenue increased 32%from 2009.New products grew 28%,and our oncology business posted a 24%increase year over year.In 2010,we successfully transitioned the critical care operations

4、 from Hospira to our operational team,expanded and trained our sales force,and implemented a marketing strategy to position the critical care business for further improvements.Critical care sales were up 21%to$50.4 million,representing almost 18%of our total revenue,and we believe these products are

5、 positioned to make solid contributions to our growth and profitability in the future.To support momentum of our custom products in the European markets,we successfully completed construction on our new plant in Slovakia and started initial product shipments beginning early this year.Favorably locat

6、ed in the center of Europe,the new facility provides us with significant distribution advantages,further expanding our international presence and enhancing our operating efficiencies.While we continued to make additional investments in research and development,and manufacturing efficiencies,we remai